RFA-CA-25-003-Full-Announcement.html

This is a Request for Application (RFA) from the National Cancer Institute (NCI) seeking innovative biospecimen science technologies for cancer research under grant number RFA-CA-25-003. The opportunity focuses on early-stage development of technologies to improve the quality and handling of cancer research samples, including tools for addressing pre-analytical degradation during collection, processing, handling, and storage of biospecimens.

The grant falls under the Cancer Detection and Diagnosis Research program (CFDA 93.394) and is administered by the Department of Health and Human Services National Institutes of Health. Eligible applicants include higher education institutions, government entities, tribal organizations, nonprofits, and small businesses. The funding supports development of tools, devices, instrumentation, and methods for cancer-relevant biospecimens, with emphasis on sample integrity preservation, quality assessment criteria, and pre-analytical degradation solutions. This initiative is part of NCI's Innovative Molecular Analysis Technologies (IMAT) Program and aims to accelerate research in cancer biology, detection, diagnosis, treatment, and health disparities.